Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between immulite 2000 XPI and dimension vista 1500

Clinical Laboratory

Volumn 58, Issue 1-2, 2012, Pages 97-105

  Zur, Berndt ^a   Holdenrieder, Stefan ^a   Walgenbach Brünagel, Gisela ^a   Albers, Eike ^a   Stoffel Wagner, Birgit ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ACCURACY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LUMINESCENT OXYGEN CHANNELING IMMUNOASSAY; PRACTICE GUIDELINE; SERUM;

ALPHA-FETOPROTEINS; CARCINOEMBRYONIC ANTIGEN; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857418060     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kinoyama S, Yamada G, Nagashima H. Ultrastructural observation of alpha-fetoprotein producing cells in human hepatocellular carcinoma using immunoperoxidase methods - comparison with fetal liver. J Gastroenterol 1986;21:152-61. (Pubitemid 16145505)
2. Kinoshita Y, Tajiri T, Souzaki R, et al. Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol 2008;30:447-50.
3. Lamerz R. Die klinische Bedeutung von Alpha-Fetoprotein bei Lebererkrankungen. Bayer Internist 1980;1:19-23.
4. Mostofi FK. Pathology of germ cell tumors of testis: a progress report. Cancer 1980;45:1735-41.
5. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010 Jun;56:e1-48.
6. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
7. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81. (Pubitemid 29265523)
8. Muraro R. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985;45:5769-80. (Pubitemid 16218586)
9. Chu DZ, Erickson CA, Russell MP, et al. Prognostic significance of carcinoembryonic antigen in colorectal carcinoma. Serum levels before and after resection and before recurrence. Arch Surg 1991;126:314-6.
10. Lamerz R, Stieber P, Borlinghaus P, Fateh-Moghadam A. Tumor markers in cancer of the liver. Diagn Oncol 1991;1:363-72.
11. Hirai H. A collaborative clinical study of carcinoembryonic antigen in Japan. Cancer Res 1977;37:2267-74.
12. Hansen HJ, Snyder JJ, Miller E, et al. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 1974;5:139-47.
13. Stieber P, Heinemann V. Sensible use of tumor markers. J Lab Med 2008;32:339-60.
14. Schalhorn A, Fuerst H, Stieber P. Tumor markers in lung cancer. J Lab Med 2001;25:353-61. (Pubitemid 33101220)
15. Molina R, Holdenrieder S, Auge JM, Schalhorn A, Hatz RA, Stieber P. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomarkers 2010;6:163-78.
16. Holdenrieder S, Nagel D, Stieber P. Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer. Cancer Biomarkers 2010;6:179-90.
17. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-22. (Pubitemid 17085741)
18. Riegman PH, Vlietstra RJ, van der Korput JA, Romijn JC, Trapman J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 1989;159:95-102. (Pubitemid 19087618)
19. Semjonow A, Hamm M, Rathert P, Hertle L. Prostate specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 1994;73:538-43. (Pubitemid 24190159)
20. O'Brian MF, Cronin AM, Feam PA, et al. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. Int J Cancer 2010;Jul 23 [Epub ahead of print].
21. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the True Number Needed to Screen and Treat to Save a Life With Prostate Specific Antigen Testing? J Clin Oncol 2010;Dec 28 [Epub ahead of print].
22. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomised European study. N Engl J Med. 2009 Mar 26;360:1320-8.
23. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Thukanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostatic-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
24. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate specific antigen ratio improves the specifity of prostate specific antigen in screening for prostate cancer in general population. J Urol 1997;157:2191-6.
25. Ullman EF, Kirakossian H, Singh S, et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994;91:5426-30. (Pubitemid 24174340)
26. Ullman EF, Kirakossian H, Switchenko AG, et al. Luminescent oxygen channelling assay (LOCI): sensitive, broadly applicable homogenous immunoassay method. Clin Chem 1996;42:1518-26. (Pubitemid 26300260)
27. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characterstic curves. J Urol 1994;152:2037-42. (Pubitemid 24354722)
28. Tanguay S, Begin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002;59:261-5. (Pubitemid 34134528)